Supernus Pharmaceuticals (SUPN) Share Value Rose While Alphaone Investment Services Decreased by $2.07 Million Its Holding; As Gilead Sciences (GILD) Valuation Declined, Holder Sector Gamma As Cut Its Stake

February 15, 2018 - By Lawrence Diaz

Alphaone Investment Services Llc decreased its stake in Supernus Pharmaceuticals Inc (SUPN) by 24.15% based on its latest 2017Q3 regulatory filing with the SEC. Alphaone Investment Services Llc sold 53,125 shares as the company’s stock rose 29.12% with the market. The institutional investor held 166,812 shares of the health care company at the end of 2017Q3, valued at $6.67M, down from 219,937 at the end of the previous reported quarter. Alphaone Investment Services Llc who had been investing in Supernus Pharmaceuticals Inc for a number of months, seems to be less bullish one the $2.02 billion market cap company. The stock increased 3.41% or $1.3 during the last trading session, reaching $39.4. About 383,946 shares traded. Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has risen 91.80% since February 15, 2017 and is uptrending. It has outperformed by 75.10% the S&P500.

Sector Gamma As decreased its stake in Gilead Sciences Inc (GILD) by 38.79% based on its latest 2017Q3 regulatory filing with the SEC. Sector Gamma As sold 212,700 shares as the company’s stock declined 8.05% while stock markets rallied. The institutional investor held 335,690 shares of the health care company at the end of 2017Q3, valued at $27.20M, down from 548,390 at the end of the previous reported quarter. Sector Gamma As who had been investing in Gilead Sciences Inc for a number of months, seems to be less bullish one the $106.88B market cap company. The stock increased 1.27% or $1.03 during the last trading session, reaching $81.82. About 7.06M shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has declined 21.80% since February 15, 2017 and is downtrending. It has underperformed by 38.50% the S&P500.

Since August 16, 2017, it had 0 insider buys, and 10 sales for $15.31 million activity. 24,250 shares valued at $1.12 million were sold by Vaughn Victor on Wednesday, January 17. Schwabe Stefan K.F. sold $4.43M worth of stock. $2.38M worth of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) was sold by PATRICK GREGORY S on Thursday, September 7.

Analysts await Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) to report earnings on February, 27. They expect $0.26 earnings per share, 0.00% or $0.00 from last year’s $0.26 per share. SUPN’s profit will be $13.33 million for 37.88 P/E if the $0.26 EPS becomes a reality. After $0.29 actual earnings per share reported by Supernus Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -10.34% negative EPS growth.

Alphaone Investment Services Llc, which manages about $491.59 million and $376.30M US Long portfolio, upped its stake in Sterling Bancorp Del (NYSE:STL) by 20,900 shares to 184,812 shares, valued at $4.56M in 2017Q3, according to the filing. It also increased its holding in Pdf Solutions Inc (NASDAQ:PDFS) by 115,200 shares in the quarter, for a total of 194,500 shares, and has risen its stake in Nn Inc (NASDAQ:NNBR).

Among 11 analysts covering Supernus Pharmaceuticals (NASDAQ:SUPN), 8 have Buy rating, 0 Sell and 3 Hold. Therefore 73% are positive. Supernus Pharmaceuticals had 36 analyst reports since August 26, 2015 according to SRatingsIntel. The company was maintained on Tuesday, September 19 by Cowen & Co. Jefferies maintained Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) rating on Thursday, August 3. Jefferies has “Buy” rating and $5100 target. The stock of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has “Buy” rating given on Thursday, August 4 by Jefferies. FBR Capital initiated the shares of SUPN in report on Wednesday, October 18 with “Buy” rating. Piper Jaffray maintained Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) rating on Friday, October 27. Piper Jaffray has “Hold” rating and $41.0 target. The rating was downgraded by Stifel Nicolaus to “Hold” on Tuesday, September 19. The firm has “Buy” rating by Cantor Fitzgerald given on Monday, November 6. The company was maintained on Friday, October 20 by Stifel Nicolaus. The stock of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) earned “Hold” rating by Piper Jaffray on Thursday, August 3. As per Monday, July 17, the company rating was maintained by Stifel Nicolaus.

Investors sentiment decreased to 0.98 in Q3 2017. Its down 0.34, from 1.32 in 2017Q2. It worsened, as 22 investors sold SUPN shares while 97 reduced holdings. 42 funds opened positions while 75 raised stakes. 48.75 million shares or 3.64% more from 47.04 million shares in 2017Q2 were reported. Chase Invest Counsel reported 11,595 shares or 0.24% of all its holdings. American Int Group Incorporated accumulated 37,920 shares. Argent Capital Mngmt Limited Company reported 0.11% of its portfolio in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). State Of Tennessee Treasury Department has invested 0.01% in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). Loring Wolcott And Coolidge Fiduciary Llp Ma holds 0% or 34 shares in its portfolio. Dekabank Deutsche Girozentrale holds 25,900 shares or 0.01% of its portfolio. First Republic Inv Mngmt Inc holds 0% or 10,933 shares. Oak Ridge Investments Limited invested in 0.28% or 174,572 shares. Granite Inv Partners Limited Liability Co holds 0.92% in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) or 371,154 shares. Group Inc One Trading Limited Partnership reported 0% stake. Globeflex Capital Limited Partnership reported 19,061 shares. Mason Street Advsrs Llc reported 12,840 shares stake. First Tru Advsrs LP owns 0.01% invested in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) for 56,376 shares. Ameritas has 0.01% invested in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) for 4,051 shares. Ubs Asset Americas reported 0.01% stake.

Since August 30, 2017, it had 0 insider purchases, and 13 selling transactions for $51.09 million activity. On Thursday, August 31 MARTIN JOHN C sold $6.09M worth of Gilead Sciences, Inc. (NASDAQ:GILD) or 73,333 shares. Shares for $8.02M were sold by Meyers James R on Tuesday, January 16. The insider Washington Robin L sold 51,820 shares worth $4.40M.

Sector Gamma As, which manages about $656.08 million US Long portfolio, upped its stake in Lexicon Pharmaceuticals Inc by 114,798 shares to 737,453 shares, valued at $9.06 million in 2017Q3, according to the filing. It also increased its holding in Anthem Inc (NYSE:ANTM) by 3,200 shares in the quarter, for a total of 182,610 shares, and has risen its stake in Mckesson Corp (NYSE:MCK).

Investors sentiment increased to 1.03 in 2017 Q3. Its up 0.10, from 0.93 in 2017Q2. It improved, as 96 investors sold GILD shares while 488 reduced holdings. 127 funds opened positions while 474 raised stakes. 957.62 million shares or 2.06% more from 938.32 million shares in 2017Q2 were reported. Grp Incorporated reported 1.84% in Gilead Sciences, Inc. (NASDAQ:GILD). Nomura Asset Limited holds 821,060 shares or 0.86% of its portfolio. Moreover, Foster Motley Incorporated has 0.12% invested in Gilead Sciences, Inc. (NASDAQ:GILD). Channing Capital Mgmt Ltd Liability Co owns 110,415 shares. Gam Holdings Ag has 0.86% invested in Gilead Sciences, Inc. (NASDAQ:GILD) for 252,949 shares. Hirtle Callaghan Limited Liability reported 0% in Gilead Sciences, Inc. (NASDAQ:GILD). Beacon Incorporated has invested 1.25% in Gilead Sciences, Inc. (NASDAQ:GILD). Arrow owns 9,201 shares. Advantus Mngmt Inc has invested 0.28% in Gilead Sciences, Inc. (NASDAQ:GILD). Moreover, Aviance Cap Partners Ltd has 0.42% invested in Gilead Sciences, Inc. (NASDAQ:GILD). Optimum Inv invested in 64,037 shares. 2.90 million were reported by Platinum Invest Management Ltd. D Scott Neal has invested 0.03% in Gilead Sciences, Inc. (NASDAQ:GILD). Utd Asset Strategies holds 3.25% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD) for 70,826 shares. State Of New Jersey Common Pension Fund D has invested 0.47% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD).

Among 30 analysts covering Gilead Sciences (NASDAQ:GILD), 21 have Buy rating, 0 Sell and 9 Hold. Therefore 70% are positive. Gilead Sciences has $137 highest and $7200 lowest target. $97.78’s average target is 19.51% above currents $81.82 stock price. Gilead Sciences had 124 analyst reports since July 29, 2015 according to SRatingsIntel. On Tuesday, January 30 the stock rating was upgraded by Citigroup to “Buy”. The firm earned “Market Perform” rating on Thursday, October 5 by Leerink Swann. The firm earned “Market Perform” rating on Thursday, October 19 by Leerink Swann. The firm has “Hold” rating given on Monday, August 28 by BMO Capital Markets. Maxim Group upgraded it to “Buy” rating and $94.0 target in Thursday, November 30 report. The rating was upgraded by Jefferies to “Buy” on Tuesday, September 6. The rating was maintained by Morgan Stanley on Wednesday, February 7 with “Equal-Weight”. Piper Jaffray maintained Gilead Sciences, Inc. (NASDAQ:GILD) on Wednesday, February 3 with “Overweight” rating. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Outperform” rating given on Tuesday, October 20 by Oppenheimer. As per Thursday, July 27, the company rating was maintained by BMO Capital Markets.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>